Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 2/20 | 0.43 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.36 |
| ▸ | SMYD3 | Q9H7B4 | 7/20 | 0.35 |
| ▸ | AHR | P35869 | 3/20 | 0.35 |
| ▸ | CMA1 | P23946 | 2/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 1/20 | 0.34 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.34 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.34 |
| ▸ | EIF2AK2 | P19525 | 1/20 | 0.34 |
| ▸ | ANPEP | P15144 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL152807 | 0.82 | HDAC3 (0.45) | HDAC3CRBNSMYD3AHRCMA1 | |
| SCHEMBL155927 | 0.81 | HDAC3 (0.44) | HDAC3CRBNSMYD3AHRCMA1 | |
| SCHEMBL155351 | 0.77 | HDAC3 (0.42) | HDAC3CRBNSMYD3AHRCMA1 | |
| SCHEMBL154464 | 0.77 | HDAC3 (0.45) | HDAC3CRBNSMYD3AHRCMA1 | |
| SCHEMBL154463 | 0.77 | HDAC3 (0.45) | HDAC3CRBNSMYD3AHRCMA1 | |
| SCHEMBL25567414 | 0.76 | HDAC3 (0.41) | HDAC3CRBNSMYD3ANPEP | |
| SCHEMBL154844 | 0.76 | SMN1; SMN2 (0.42) | HDAC3CRBNSMYD3HDAC1 | |
| SCHEMBL12016987 | 0.74 | USP2 (0.42) | HDAC3CRBNSMYD3HDAC1 | |
| SCHEMBL155059 | 0.73 | HDAC3 (0.41) | HDAC3CRBNSMYD3GRIN1GRIN2B | |
| SCHEMBL159194 | 0.73 | HDAC3 (0.39) | HDAC3CRBNSMYD3HDAC1EIF2AK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8329682-B2 | Pyrrolo-nitrogenous heterocyclic derivatives, the preparation and the pharmaceutical use thereof | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) | 2012-12-11 | — | — | US | disclosed |
| US-20100075952-A1 | PYRROLO-NITROGENOUS HETEROCYCLIC DERIVATIES,THE PREPARATION AND THE PHARMCETICAL USE THEEOF | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD (CN) | 2010-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100075952-A1 | PYRROLO-NITROGENOUS HETEROCYCLIC DERIVATIES,THE PREPARATION AND THE PHARMCETICAL USE THEEOF | MTOR, PKN2, MAP3K15 | HDAC3 1925/4885CRBN 1716/4885SMYD3 2630/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.